Barclays
GLUE icon

Barclays’s Monte Rosa Therapeutics GLUE Stock Holding History

Barclays’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$187K Sell
11,353
-124,631
-92% -$2.38M ﹤0.01% 3726
2025
Q4 		$2.13M Buy
135,984
+63,029
+86% +$849K ﹤0.01% 2881
2025
Q3 		$541K Sell
72,955
-12,757
-15% -$67.6K ﹤0.01% 3764
2025
Q2 		$387K Buy
85,712
+39,502
+85% +$176K ﹤0.01% 3904
2025
Q1 		$214K Sell
46,210
-24,531
-35% -$150K ﹤0.01% 4002
2024
Q4 		$491K Buy
70,741
+16,233
+30% +$122K ﹤0.01% 3837
2024
Q3 		$289K Buy
54,508
+43,499
+395% +$220K ﹤0.01% 4109
2024
Q2 		$41.2K Sell
11,009
-10,739
-49% -$54.8K ﹤0.01% 4284
2024
Q1 		$153K Sell
21,748
-39,520
-65% -$234K ﹤0.01% 4245
2023
Q4 		$346K Buy
61,268
+48,097
+365% +$189K ﹤0.01% 4117
2023
Q3 		$63.1K Sell
13,171
-464
-3% -$2.99K ﹤0.01% 3768
2023
Q2 		$93.4K Sell
13,635
-1,534
-10% -$9.92K ﹤0.01% 3588
2023
Q1 		$118K Buy
15,169
+7,181
+90% +$49.9K ﹤0.01% 4091
2022
Q4 		$60.8K Buy
7,988
+6,772
+557% +$56.4K ﹤0.01% 4469
2022
Q3 		$10K Sell
1,216
-224
-16% -$2.06K ﹤0.01% 4298
2022
Q2 		$14K Sell
1,440
-7,668
-84% -$77K ﹤0.01% 4517
2022
Q1 		$128K Buy
+9,108
New +$126K ﹤0.01% 3676

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Barclays's GLUE Position: Q1 2026 in Review

Barclays reduced its Monte Rosa Therapeutics (GLUE) stake by 92% in Q1 2026, selling an estimated $2.38M and leaving 11,353 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #3726.

Barclays first reported a position in GLUE in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.13M in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Barclays held 11,353 shares of Monte Rosa Therapeutics worth $187K as of Q1 2026.
  • Barclays sold 124,631 Monte Rosa Therapeutics shares in Q1 2026, an estimated $2.38M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3726 holding.
  • Barclays first reported a position in Monte Rosa Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Monte Rosa Therapeutics position peaked at $2.13M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.